Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219088 | 1.00 | PYGM (0.38) | PYGMTDP1LMNACRBNAKR1B1 | |
| SCHEMBL15216893 | 0.82 | LMNA (0.37) | PYGMTDP1LMNACRBNAKR1B1 | |
| SCHEMBL15219049 | 0.81 | CRBN (0.36) | TDP1CRBN | |
| SCHEMBL15014721 | 0.81 | CRBN (0.36) | TDP1CRBN | |
| SCHEMBL15216897 | 0.80 | PYGM (0.45) | PYGMTDP1CRBN | |
| SCHEMBL18133096 | 0.80 | PYGM (0.45) | PYGMTDP1CRBN | |
| SCHEMBL21150675 | 0.74 | CRBN (0.37) | PYGMCRBNAKR1B1 | |
| SCHEMBL15219087 | 0.70 | TDP1 (0.40) | TDP1LMNACRBN | |
| SCHEMBL17057390 | 0.69 | GAA (0.40) | TDP1LMNACRBN | |
| SCHEMBL15216895 | 0.69 | GAA (0.40) | TDP1LMNACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2602261-B1 | BORON COMPOUND WITH AMINO ACID SKELETON CONTAINING CYCLIC RING | STELLA PHARMA CORP (JP) | 2016-10-12 | — | — | EP | disclosed |
| US-8907128-B2 | Boron compound with amino acid skeleton containing cyclo ring-type ring | STELLA PHARMA CORPORATION (JP) | 2014-12-09 | — | — | US | disclosed |
| US-8907128-B2 | Boron compound with amino acid skeleton containing cyclo ring-type ring | STELLA PHARMA CORPORATION (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | STELLA PHARMA CORPORATION (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | STELLA PHARMA CORPORATION (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | BCAT1, BCAT2, SLC1A5 | PYGM 2441/4885TDP1 3968/4885LMNA 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.